HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx-to-OTC Switch

Set Alert for Rx-To-OTC Switch

Longer Exclusivity Periods For EU Centralized Rx-To-OTC Switches? Commission Says No

One way to revitalize interest in the EU's centralized switch procedure would be to introduce longer data exclusivity periods or market exclusivity for successful applicants, concluded an AESGP expert switch panel presenting at the association's 59th Annual Meeting in Paris, France. However, a European Commission representative told another panel that this was not under consideration as part of the EU pharmaceutical legislation revision.

Europe Health

Pending Decision On First US OTC Birth Control Shines Spotlight On Self-Report Study Data

Approval likely would account for all weight on scale of FDA decision if not for self-report element in design of HRA Pharma’s actual use study for OTC switch of 0.075-mg norgestrel branded Opill. HRA’s sNDA offers lesson for using electronic diary apps in self-report studies.

FDA Prescription To OTC Switch

AESGP Annual Meeting: OTC Antifungals, Antivirals Could Become Rx In EU

The European Commission shocked participants at this year's AESGP Annual Meeting by warning that OTC antifungals, like treatments for athlete’s foot, and OTC antivirals, like cold sore creams, could soon become prescription-only within the region, under proposed revisions to the EU pharma legislation. There is hope, however. The proposals are still open to feedback from industry, the AESGP points out, and even if this proposal becomes law, member states can waive this prescription requirement under certain conditions.

Europe Health

Over The Counter 22 May 2023: What You Need To Know About HRA’s Historic US OTC Pill Switch With HBW’s Malcolm Spicer

HBW Insight catches up with US executive editor, Malcolm Spicer, to discuss Perrigo subsidiary HRA Pharma’s Rx-to-OTC switch application for its daily contraceptive, Opill. With the switch currently under consideration by the US Food and Drug Administration after a positive recommendation from its advisory committees, Spicer draws on his in depth coverage of the subject, as well as his extensive experience writing about the US consumer health market, to tell listeners what they need to know about this historic switch.

US States Health

Advisory Panel Members On Unanimous Vote Recommending US FDA Approve OTC Birth Control

NDAC and ORUDAC members acknowledged the FDA’s concerns about some data provided by Opill sponsor HRA Pharma to support its OTC switch application. However, a greater share noted the “historic nature” of the proposal and the broad support expressed in the meeting’s public comment portion.

Prescription To OTC Switch Women's Health

UK Rejects Rx-To-OTC Switch Of Overactive Bladder Treatment

Maxwellia’s application to switch to non-prescription status in the UK Aquiette (oxybutynin hydrochloride) for the treatment of overactive bladder has been rejected by MHRA following a public consultation.

Prescription To OTC Switch United Kingdom

Year After Acquisition, Perrigo Waits For US Decision On HRA’s OTC Oral Contraceptive Switch

Wait will be as long as another three months to learn whether HRA will have approval to market OTC a product Perrigo estimates will have $100m in annual sales.

FDA Women's Health

First OTC Oral Contraceptive Has Advisory Panel’s Unanimous Support Despite FDA’s Data Concerns

FDA officials again made clear concerns about “improbable dosing” data in HRA’s sNDA for 0.075-mg norgestrel tablet branded Opill before advisory panel voted at close of a two-day meeting conducted 60 years after first Rx oral contraceptive approved in US.

FDA Drug Approval Standards
See All